14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
LYRA vs ANRO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). LYRA carries a Unified Composite Score of 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin), whereas ANRO carries 34.3/100 (SELL) at $25.12 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. ANRO 34.3/100 SELL), ANRO captures the overall institutional head-to-head verdict (6–1 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -25032.0% operating margin) and revenue trajectory (+0.0% vs. -87.2% YoY).
Technical & Structure Timing Caution: LYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5); meanwhile ANRO is in a Breakdown options structure phase (RSI 48.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LYRA vs ANRO. Trailing 12-month operating profitability (LYRA -25032.0% vs ANRO 0.0%) and valuation multiples (LYRA N/M vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ LYRA vs ANRO Key Questions & Quantitative Answers
As of Nov 17, 2026, Alto Neuroscience Inc. (ANRO) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). LYRA carries a Unified Composite Score of 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin), whereas ANRO carries 34.3/100 (SELL) at $25.12 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. ANRO 34.3/100 SELL), ANRO captures the overall institutional head-to-head verdict (6–1 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -25032.0% operating margin) and revenue trajectory (+0.0% vs. -87.2% YoY). Technical & Structure Timing Caution: LYRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5); meanwhile ANRO is in a Breakdown options structure phase (RSI 48.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ANRO leads the Growth & Scale pillar: LYRA posts -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin), compared with ANRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, LYRA generates $600,000 in USD-normalized revenue versus N/A for ANRO. In operating R&D and SG&A reinvestment, LYRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANRO.
LYRA screens cheaper on headline valuation multiples. LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin), whereas ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LYRA (-404.5% ROE) versus ANRO (-46.7% ROE) capital efficiency.
In options market volatility and institutional positioning, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk). By comparison, ANRO carries 79.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (2.03β · 94% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.